Myovant Sciences Ltd (NYSE:MYOV) Insider Frank Karbe Purchases 8,000 Shares

Myovant Sciences Ltd (NYSE:MYOV) insider Frank Karbe purchased 8,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $9.10 per share, with a total value of $72,800.00. Following the completion of the acquisition, the insider now owns 8,000 shares of the company’s stock, valued at $72,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of MYOV traded down $0.31 on Tuesday, reaching $8.89. 196,402 shares of the stock traded hands, compared to its average volume of 185,157. The stock has a market cap of $705.38 million, a PE ratio of -2.17 and a beta of 1.31. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 21.51. Myovant Sciences Ltd has a 12 month low of $8.69 and a 12 month high of $27.45.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley grew its position in Myovant Sciences by 180.9% in the first quarter. Morgan Stanley now owns 3,590 shares of the company’s stock valued at $85,000 after acquiring an additional 2,312 shares during the period. BlackRock Inc. grew its position in Myovant Sciences by 5.2% in the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock valued at $458,000 after acquiring an additional 1,386 shares during the period. Swiss National Bank grew its position in Myovant Sciences by 3.3% in the first quarter. Swiss National Bank now owns 31,200 shares of the company’s stock valued at $745,000 after acquiring an additional 1,000 shares during the period. Bank of New York Mellon Corp grew its position in Myovant Sciences by 3,012.4% in the fourth quarter. Bank of New York Mellon Corp now owns 369,320 shares of the company’s stock valued at $6,060,000 after acquiring an additional 357,454 shares during the period. Finally, Norges Bank bought a new stake in Myovant Sciences in the fourth quarter valued at $12,308,000. Institutional investors and hedge funds own 30.56% of the company’s stock.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Myovant Sciences from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Wednesday, April 3rd. Evercore ISI assumed coverage on Myovant Sciences in a report on Thursday, April 11th. They set an “outperform” rating for the company. ValuEngine lowered Myovant Sciences from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. JMP Securities reiterated a “buy” rating and set a $25.00 price target on shares of Myovant Sciences in a report on Monday, February 11th. Finally, Barclays upgraded Myovant Sciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $22.00 to $25.00 in a report on Wednesday, February 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $26.83.

TRADEMARK VIOLATION WARNING: “Myovant Sciences Ltd (NYSE:MYOV) Insider Frank Karbe Purchases 8,000 Shares” was published by Sundance Herald and is the property of of Sundance Herald. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://sundanceherald.com/2019/06/11/myovant-sciences-ltd-nysemyov-insider-frank-karbe-purchases-8000-shares.html.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Recommended Story: Buy-Side Analysts

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply